Freeline Therapeutics Holdings plc (NASDAQ:FRLN – Get Rating) – Equities researchers at HC Wainwright cut their FY2026 earnings estimates for Freeline Therapeutics in a research note issued to investors on Tuesday, November 22nd. HC Wainwright analyst P. Trucchio now expects that the company will earn $0.27 per share for the year, down from their previous estimate of $0.28. HC Wainwright currently has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for Freeline Therapeutics’ current full-year earnings is ($1.65) per share.
Separately, BTIG Research reduced their price target on shares of Freeline Therapeutics from $10.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday, August 11th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $10.00.
Freeline Therapeutics Stock Performance
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the company. Acadian Asset Management LLC bought a new position in shares of Freeline Therapeutics in the first quarter worth approximately $30,000. Prospera Financial Services Inc grew its holdings in shares of Freeline Therapeutics by 130.3% in the first quarter. Prospera Financial Services Inc now owns 34,650 shares of the company’s stock worth $39,000 after purchasing an additional 19,603 shares during the last quarter. Federated Hermes Inc. grew its holdings in shares of Freeline Therapeutics by 50.0% in the first quarter. Federated Hermes Inc. now owns 60,000 shares of the company’s stock worth $67,000 after purchasing an additional 20,000 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of Freeline Therapeutics by 112.5% in the first quarter. Renaissance Technologies LLC now owns 446,412 shares of the company’s stock worth $500,000 after purchasing an additional 236,312 shares during the last quarter. Finally, UBS Group AG bought a new position in shares of Freeline Therapeutics in the first quarter worth approximately $565,000. Institutional investors own 58.48% of the company’s stock.
About Freeline Therapeutics
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B.
- Get a free copy of the StockNews.com research report on Freeline Therapeutics (FRLN)
- Microsoft Shares: Is it Time to Back Up the Truck?
- Institutional Support for Analog Devices Remains High
- Is the 60/40 Portfolio Mix Still in Vogue?
- Three CBD Stocks to Dominate a Budding Industry
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
Receive News & Ratings for Freeline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Freeline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.